CD4 and primary cutaneous T-cell non-Hodgkin lymphoma: Moreover, a recent study found that GD3, which is overexpressed on the surface of cutaneous T-cell lymphoma cells (CTCL), inhibits IL-17 production from healthy CD4+ T-cells in the tumor microenvironment, compromising cancer immunosurveillance, thus allowing malignant cells to proliferate unsuppressed [202].